« September 2006 | Main | November 2006 »
Girls diagnosed with ADHD in elementary school are at greater risk than teenagers for substance abuse, delinquency, failure in school, early sexual activity, low self-worth and poor friendships, says a longitudinal study from the University of California, Berkeley.
October 10—Shire plc announced today that its collaborative partner New River Pharmaceuticals Inc. has received an approvable letter from the U.S. Food and Drug Administration for NRP104 (lisdexamfetamine dimesylate), for the treatment of pediatric ADHD. According to the FDA's letter, marketing approval of NRP104 is contingent upon final scheduling by the U.S. Drug Enforcement Administration. No additional studies have been requested by the FDA as a condition for approval of NRP104. Shire and New River will continue dialog with FDA officials to agree upon a final trade name. Shire and New River Pharmaceuticals are preparing for a product launch (Medical News)
Can Shire Cash In? The new drug is thought to be an improvement on the older treatment because it is less susceptible to abuse. Following approval, NRP104 is expected to offer patients, their families, and healthcare providers an important new treatment for ADHD, attention deficit hyperactivity disorder.
Although the FDA has suggested the drug is placed in schedule two of the Controlled Substances Act, which means it has a "high potential" for misuse - the same level as Adderall XR.